38,634 Shares in Danaher Corporation $DHR Purchased by NBT Bank N.A.

NBT Bank N.A. purchased a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 38,634 shares of the conglomerate’s stock, valued at approximately $8,559,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. BlackRock Inc. purchased a new stake in shares of Danaher in the second quarter valued at $10,492,520,000. Wellington Management Group LLP grew its holdings in shares of Danaher by 10.4% during the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after buying an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of Danaher during the second quarter valued at $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher during the second quarter valued at $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher during the second quarter valued at $993,846,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Sunday, October 18th. Wells Fargo & Company decreased their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. JPMorgan Chase & Co. lifted their target price on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group reiterated a “buy” rating and issued a $260.00 target price on shares of Danaher in a report on Thursday. Finally, TD Cowen increased their price target on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $242.91.

Danaher Trading Down 1.7%

NYSE DHR opened at $229.86 on Friday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $161.59 billion, a PE ratio of 40.83, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. The firm’s fifty day simple moving average is $215.76 and its 200-day simple moving average is $197.12.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to analyst estimates of $6.56 billion. Danaher had a return on equity of 11.22% and a net margin of 16.91%. Danaher’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company earned $1.89 earnings per share. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.51 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook.
• Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO
• Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.